The risk or severity of adverse effects can be increased when Morphine is combined with Valsartan. Valsartan may increase the hypotensive activities of Bepridil. The risk or severity of adverse effects can be increased when Valsartan is combined with Castanospermine. The risk or severity of adverse effects can be increased when Valsartan is combined with Apremilast. Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Valsartan. The metabolism of Gavestinel can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Masoprocol. The risk or severity of adverse effects can be increased when Valsartan is combined with Evening primrose oil. The risk or severity of adverse effects can be increased when Valsartan is combined with Labetalol. Valsartan may increase the hypotensive activities of Fenoldopam. The risk or severity of adverse effects can be increased when Valsartan is combined with Balsalazide. The risk or severity of adverse effects can be increased when Valsartan is combined with Benazepril. The metabolism of Acetaminophen can be decreased when combined with Valsartan. The metabolism of Lidocaine can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Nitroglycerin. Valsartan may increase the hypotensive activities of Vincamine. The metabolism of Formoterol can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Omapatrilat. The metabolism of Arachidonic Acid can be decreased when combined with Valsartan. Rasagiline may increase the hypotensive activities of Valsartan. The metabolism of Chlorpropamide can be decreased when combined with Valsartan. The metabolism of Cyclophosphamide can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Trandolapril. The risk or severity of adverse effects can be increased when Valsartan is combined with Nadolol. The risk or severity of adverse effects can be increased when Valsartan is combined with Alclofenac. The serum concentration of Carvedilol can be increased when it is combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Metamizole. Ardeparin may increase the hyperkalemic activities of Valsartan. The risk or severity of adverse effects can be increased when Desflurane is combined with Valsartan. Valsartan may increase the hypotensive activities of Risperidone. Toloxatone may increase the hypotensive activities of Valsartan. Pivhydrazine may increase the hypotensive activities of Valsartan. The metabolism of Glyburide can be decreased when combined with Valsartan. The metabolism of Rosiglitazone can be decreased when combined with Valsartan. The metabolism of Vismodegib can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Semapimod. The risk or severity of adverse effects can be increased when Arotinolol is combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Quinapril. The metabolism of Valsartan can be decreased when combined with Lobeglitazone. The risk or severity of adverse effects can be increased when Valsartan is combined with Riociguat. Valsartan may increase the hypotensive activities of Guanabenz. Furazolidone may increase the hypotensive activities of Valsartan. The serum concentration of Valsartan can be increased when it is combined with Mifepristone. The metabolism of Alosetron can be decreased when combined with Valsartan. Brimonidine may increase the antihypertensive activities of Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Mononitrate. The risk or severity of adverse effects can be increased when Ropivacaine is combined with Valsartan. Valsartan may increase the orthostatic hypotensive activities of Duloxetine. The metabolism of Brivaracetam can be decreased when combined with Valsartan. The metabolism of Dextromethorphan can be decreased when combined with Valsartan. Quinine may increase the hypotensive activities of Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Enalaprilat. The risk or severity of adverse effects can be increased when Valsartan is combined with Indoprofen. The metabolism of Valsartan can be decreased when combined with Fluvoxamine. Valsartan may increase the hypotensive activities of Selexipag. The risk or severity of adverse effects can be increased when Valsartan is combined with PTC299. The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Valsartan. Valsartan may increase the hypotensive activities of Bupranolol. The risk or severity of adverse effects can be increased when Valsartan is combined with Dinutuximab. The serum concentration of Valsartan can be decreased when it is combined with Lumacaftor. The metabolism of Ketobemidone can be decreased when combined with Valsartan. Octamoxin may increase the hypotensive activities of Valsartan. Mirodenafil may increase the antihypertensive activities of Valsartan. Tolvaptan may increase the hyperkalemic activities of Valsartan. The metabolism of Valsartan can be decreased when combined with Delavirdine. Methohexital may increase the hypotensive activities of Valsartan. The metabolism of Valsartan can be increased when combined with Phenytoin. Udenafil may increase the antihypertensive activities of Valsartan. Trimazosin may increase the hypotensive activities of Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Nimodipine. The risk or severity of adverse effects can be increased when Valsartan is combined with Metoprolol. The risk or severity of adverse effects can be increased when Valsartan is combined with Salicylamide. The risk or severity of adverse effects can be increased when Valsartan is combined with Pindolol. The risk or severity of adverse effects can be increased when Valsartan is combined with Bendroflumethiazide. The metabolism of Ketamine can be decreased when combined with Valsartan. The metabolism of Valsartan can be increased when combined with Rifampicin. The risk or severity of adverse effects can be increased when Valsartan is combined with Nepafenac. Parnaparin may increase the hyperkalemic activities of Valsartan. Certoparin may increase the hyperkalemic activities of Valsartan. The metabolism of Aminophenazone can be decreased when combined with Valsartan. The metabolism of Nevirapine can be decreased when combined with Valsartan. The metabolism of Tenoxicam can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Tizanidine. The risk or severity of adverse effects can be increased when Valsartan is combined with E-6201. Valsartan may increase the hypotensive activities of Niguldipine. The metabolism of Paramethadione can be decreased when combined with Valsartan. The metabolism of Rupatadine can be decreased when combined with Valsartan. The metabolism of Suprofen can be decreased when combined with Valsartan. Amobarbital may increase the hypotensive activities of Valsartan. The metabolism of Bexarotene can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Rescinnamine. Valsartan may increase the hypotensive activities of Efonidipine. The risk or severity of adverse effects can be increased when Valsartan is combined with Fosinopril. Ketanserin may increase the hypotensive activities of Valsartan. The metabolism of Fluoxetine can be decreased when combined with Valsartan. The metabolism of Ximelagatran can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Bromfenac. The risk or severity of adverse effects can be increased when Pramipexole is combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Resveratrol. The risk or severity of adverse effects can be increased when Valsartan is combined with Lisinopril. The risk or severity of adverse effects can be increased when Valsartan is combined with Adapalene. Valsartan may increase the hypotensive activities of Macitentan. The metabolism of Valsartan can be decreased when combined with Capecitabine. The risk or severity of adverse effects can be increased when Valsartan is combined with Azilsartan medoxomil. The risk or severity of adverse effects can be increased when Valsartan is combined with Betaxolol. The metabolism of Theophylline can be decreased when combined with Valsartan. The metabolism of Valsartan can be decreased when combined with Indinavir. Valsartan may increase the hypotensive activities of Saprisartan. The metabolism of Flunarizine can be decreased when combined with Valsartan. Valsartan may increase the hypotensive activities of Amifostine. The risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid. The risk or severity of adverse effects can be increased when Valsartan is combined with Carbaspirin calcium. Valsartan may increase the hypotensive activities of Remikiren. Valsartan may increase the hypotensive activities of Manidipine. The metabolism of Indomethacin can be decreased when combined with Valsartan. Reviparin may increase the hyperkalemic activities of Valsartan. The metabolism of Valsartan can be decreased when combined with Sulfadiazine. Phenelzine may increase the hypotensive activities of Valsartan. Tadalafil may increase the antihypertensive activities of Valsartan. The therapeutic efficacy of Valsartan can be decreased when used in combination with Acemetacin. The risk or severity of adverse effects can be increased when Valsartan is combined with Nitroaspirin. The metabolism of Netupitant can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Reserpine. Methylene blue may increase the hypotensive activities of Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Serrapeptase. The metabolism of Valsartan can be decreased when combined with Sulfamethoxazole. The metabolism of Paclitaxel can be decreased when combined with Valsartan. The serum concentration of Valsartan can be increased when it is combined with Ceritinib. The risk or severity of adverse effects can be increased when Valsartan is combined with Indobufen. The risk or severity of adverse effects can be increased when Valsartan is combined with Felodipine.